Purchase this article with an account.
Xiaoping Qi, Jun Cai, William W. Hauswirth, Sanford Boye, Qiuhong Li, Renee Ryals, Li Liu, Zhijuan Chen, Maria B. Grant, Michael E. Boulton; -Secretase Is A Critical Regulator Of Laser-induced CNV In The Mouse. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1795.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We have previously shown that pigment epithelial-derived factor (PEDF) inhibits VEGF-induced in vitro angiogenesis via a γ-secretase dependent pathway (Cai et al, J Biol Chem 2006). The aims of this study were to first determine if PEDF inhibition of CNV was dependent on γ-secretase and second to assess whether viral-mediated overexpression of presenilin-1 (PS-1) alone, a critical subunit of the γ-secretase complex, could also inhibit CNV.
Mice received intravitreal PEDF in the presence or absence of the γ-secretase inhibitors (DAPT, L685485) immediately following laser induction of CNV. Animals were sacrificed 14 days post laser and the volume of CNV lesions was quantified. For viral-mediated overexpression, the mouse PS-1 gene driven by the VE-cadherin promoter was tagged with HA and inserted into a recombinant quadruple mutant adeno-associated virus serotype 2 (AAV2-VEc-PS-1). For in vitro studies, bovine retinal microvascular endothelial cells were infected with AAV2-VEc-PS-1 or control virus and 1) PS-1 expression was determined by PCR and Western blot and 2) the effect on in vitro angiogenesis was assessed in the Matrigel tube forming assay. The effect of PS-1 overexpression on CNV was assessed by subretinal injection of AAV2-VEc-PS-1 or control virus followed by laser induction of CNV 3 weeks later.
PEDF induced a greater than 60% (p<0.001) reduction in CNV which was completely blocked by either γ-secretase inhibitor confirming γ-secretase as a critical regulator of CNV. Transfection of cultured retinal endothelial cells with AAV2-VEc-PS-1resulted in a greater than 40% overexpression in PS-1 which reduced tubule formation in the Matrigel assay by 45% compared to control (p<0.05). After subretinal delivery of AAV2-VEc-PS-1, PS-1 expression was increased 1.5 fold (p<0.05) and PS-1 was localized to vessels of both the retinal and choroid. Subretinal AAV2-VEC-PS-1 injection resulted in a 65% reduction in CNV lesion size (p<0.001). This was associated with an increase in mRNA levels of the antioxidant enzymes (SOD1, SOD2, GST) and a decrease in proinflammatory cytokines (MCP1, Rantes, TNFα) in the posterior cups.
Increasing the activity of γ-secretase or increasing the expression of the key component of γ-secretase, PS-1, may represent novel therapeutic strategies for treatment of CNV.
This PDF is available to Subscribers Only